Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the antihypertensive and neuroprotective effects of Hyzaar(R) in elderly subjects in comparison with Natrilix(TM).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Antihypertensive Agents; Hydrochlorothiazide; Losartan

Criteria

Inclusion Criteria:

• ACEi or ARB naive or not taking ACEi or ARB concurrently for at least one month before the run-in period

• Be able to carry out his or her own daily activity

• - Be at least 50 years old at inclusion in the study Be diagnosed with mild to moderate hypertension, treated or untreated

• Literate

• Not taking any cognitive-enhanced agent at baseline

• Present with a memory complain ( spontaneous or informed by caregiver)

Exclusion Criteria:

• Congestive heart failure with NYHA class >2

• Renal failure or renal insufficiency with serum creatinine >1.4mg/dl

• chronic severe liver disease with abnormal GPT and GOT >2 times of upper normal limits

• Diagnosed with major depression when entering the study

• Foreign language as his or her mother tongue so that the test results will not be reliable

• History of stroke or transient ischemic attack (stroke is defined as focal neurological sign progressing stepwise)

• Hypersensitive to the active ingredient and any other component of losartan potassium and indapamide tablets

• Major hearing loss/deafness and/or major visual impairment/blindness preventing from performing the tests

• Myocardial infarction within the past 6 months

• Single functioning kidney

• Anuria